Study #2023-0254
Open-label phase 1b study of Ulixertinib and Cetuximab or Ulixertinib in combination with Cetuximab and Encorafenib in patients with unresectable or metastatic Colorectal Cancer who have previously received EGFR or BRAF-directed therapy
MD Anderson Study Status
Enrolling
Treatment Agent
Cetuximab, Ulixertinib, Encorafenib
Description
To find the recommended dose of ulixertinib that can be given in combination with cetuximab and/or encorafenib to patients with unresectable/metastatic CRC and who have received EGFR or BRAF-directed therapy in the past.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Colorectal Cancer
Study phase:
Phase I
Physician name:
Christine Parseghian
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-421-1842
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.